The Efficacy, Tolerability, and Benefits of 750 mg Once-Daily Levofloxacin in the Treatment of Community-Acquired Pneumonia (Interview with Prof. Thomas M. File, Jr, MD, MS )

21 June, 2018

file_4 name_4

Question

Preclinical scientific rationale for High-Dose Levofloxacin Dose Schedule

Q01	What is the scientific rationale for using 750mg levofloxacin in CAP?
Q02	What are the PK/PD differences between the 500mg and 750mg dose?
Q03	How do the PK/PD features of the 750mg dose result in microbiological effects?
Q04	What clinical benefits are derived from the PK/PD features of the 750 mg dose?

Results of Clinical studies investigating High-Dose Levofloxacin

Q05	Summary of clinical studies investigating 750mg dose
Q06	Comparison between 750mg levofloxacin and other FQ in CAP
Q07	Comparison between 750mg levofloxacin and other non-FQ comparator agents in CAP.

Clinical Advantages Associated with High-Dose Levofloxacin in CAP

Q08	What effect does high-dose levofloxacin have on duration of therapy?
Q09	Does the High-Dose schedule have an effect on the development of resistance?
Q10	Effect of High-Dose therapy on Compliance
Q11	Advantages of Shorter Duration of IV therapy
Q12	Who should be treated with high-dose levofloxacin?

Safety Issues Relating to High-Dose Levofloxacin

Q13	What is the safety profile of the 750mg schedule?
Q14	Are there any patient groups in whom high-dose therapy is contraindicated?
Q15	Differences in the safety profile of 750mg levofloxacin versus other FQ?